Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab and SOX with or without Trastuzumab in HER2+ Gastric Cancer
NCT05583383Phase 2Unknown
- Sponsor
- Henan Cancer Hospital
- Start
- Mar 2022
- Primary completion
- Mar 2025
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Henan Cancer Hospital. Status: unknown.
02
Drugs
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT05583383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05583383.